Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
US |
|
Sahara International Petrochemical Co SJSC
SAU:2310
|
SA |
|
Microequities Asset Management Group Ltd
ASX:MAM
|
AU |
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
US |
|
S
|
Sewoo Global Co Ltd
KRX:013000
|
KR |
|
Jadwa REIT Saudi Fund
SAU:4342
|
SA |
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
IN |
|
G
|
Gofore Oyj
OMXH:GOFORE
|
FI |
|
S
|
Sagility India Ltd
NSE:SAGILITY
|
IN |
|
Totens Sparebank
OSE:TOTG
|
NO |
|
P
|
PayPal Holdings Inc
XETRA:2PP
|
US |
|
Shinhung Co Ltd
KRX:004080
|
KR |
|
Iris Energy Ltd
NASDAQ:IREN
|
AU |
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
